Eli Lilly has unveiled a series of strategic partnerships and platforms designed to leverage artificial intelligence across its R&D pipeline. In September, the company introduced TuneLab, an AI-driven drug-discovery platform offered free to emerging biotech firms; in exchange for access to Lilly’s proprietary algorithms, partner companies contribute data to further refine the models. In October, Lilly announced a collaboration with NVIDIA to build what it describes as the most powerful AI supercomputer in the pharmaceutical sector, dedicated to tasks ranging from molecular modeling to virtual screening. Most recently, Lilly and NVIDIA committed to establishing a joint AI research laboratory in the San Francisco Bay Area, staffed by Lilly scientists and NVIDIA engineers, with the goal of reducing cycle times for lead identification by up to 50%. Collectively, these initiatives are expected to lower R&D costs by several hundred million dollars annually once fully operational, while potentially shaving years off the timeline for first-in-class candidates.

In its latest 13F filing, First Citizens Bank & Trust Co. increased its stake in Eli Lilly by nearly 60% during the third quarter, bringing its total holdings to just under 25,000 shares. This follows smaller, yet notable, acquisitions by Sumitomo Mitsui Financial Group, Evolution Wealth Management, and other boutique investment firms, each deploying between $27,000 and $31,000 into Lilly stock. Overall, institutional ownership now accounts for over 82% of shares outstanding, underscoring confidence from hedge funds and asset managers in both Lilly’s near-term growth drivers and its long-term pipeline prospects.

Eli Lilly reported third-quarter revenue growth of 53.9% year-over-year, delivering $17.6 billion in top-line sales and $7.02 in earnings per share—beating consensus forecasts by $0.60. Net margin expanded to 31.0%, while return on equity exceeded 109%, reflecting strong operating leverage. The company raised its full-year EPS guidance to a range of 23.00–23.70, driven by continued momentum in its weight-management franchise and newly launched immunology assets. To reward shareholders, Lilly boosted its quarterly dividend by 15% to $1.73 per share, representing a payout ratio near 29% and signaling management’s confidence in cash flow generation through ongoing patent expirations.